Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMP2794
- Development stage
- Preclinical
- Lead developer
- IMPACT Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
IMP2794 is an orally bioavailable, highly selective proteolysis-targeting chimera (PROTAC) designed to degrade lysine acetyltransferase 6A (KAT6A). Developed by IMPACT Therapeutics using its proprietary targeted protein degradation (TPD) platform, IMP2794 exhibits over 1,000-fold selectivity for KAT6A over its homolog KAT6B, thereby minimizing the risk of hematopoietic toxicities associated with KAT6B inhibition. In preclinical studies, the candidate has demonstrated potent in vitro cytotoxicity against tumor cells and significant in vivo antitumor efficacy in both sensitive and insensitive breast cancer cell line-derived xenograft (CDX) models. It is being developed for the treatment of advanced solid tumors, particularly estrogen receptor-positive (ER+) breast cancer.
02
Targets
KAT6A (Lysine acetyltransferase 6A)
Beyond the preview
Go deeper on IMP2794.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMP2794.